Axsome Therapeutics Inc $ 78.07 0.03 (0.04%)
Volume:
391,558
Avg Vol (1m):
501,597
Market Cap $:
2.89 Bil
Enterprise Value $:
2.72 Bil
P/E (TTM):
0.00
P/B:
18.54
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 9.81 | ||
| Debt-to-Equity | 0.13 | ||
| Debt-to-EBITDA | -0.23 | ||
| Piotroski F-Score | 3 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| ROE % | -117.63 | ||
| ROA % | -80.32 | ||
| ROC (Joel Greenblatt) % | -244986.26 | ||
| 3-Year EBITDA Growth Rate | -11.8 | ||
| 3-Year EPS without NRI Growth Rate | -12.3 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 18.54 | ||
| EV-to-EBIT | -30.47 | ||
| EV-to-EBITDA | -30.48 | ||
| Current Ratio | 7.57 | ||
| Quick Ratio | 7.57 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -24.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 18.54 | ||
| Earnings Yield (Greenblatt) % | -3.28 |